Tiziana Life Sciences, Ltd. (TLSA) Tuesday reported encouraging results from an open-label study evaluating nasal foralumab for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS).
Results from the study showed that all patients treated with nasal foralumab experienced stabilization of their Expanded Disability Status Scale (EDSS) scores; Fatigue improved in six out of ten patients; TSPO-PET imaging showed significant reductions in microglial activation at six months; and no serious or severe treatment-related adverse events were reported.
Tiziana has initiated a Phase 2 study to further assess the efficacy and safety of nasal foralumab in a larger cohort of patients with na-SPMS. Top line data from the study is expected at the end of the year.
For comments and feedback: editorial@rttnews.com